Top 3 drug approvals in oncology: August 2021

Written by Jade Parker, Senior Editor

cancer drug approvals august

Over the past month, several oncology drugs have been newly approved; in this piece we provide you with the key facts to keep you up-to-date with the industry news. Highlights include the approval of Opdivo® plus Yervoy® by the Medicines and Healthcare products Regulatory Agency (MHRA)  and Verzenios® with Faslodex® by NICE in the UK. Opdivo (nivolumab) plus Yervoy (ipilimumab) Approved: 5 August 2021 Company: Bristol Myers Squibb (NY, USA) Indication: Inoperable pleural mesothelioma “The approval of nivolumab plus ipilimumab is the first drug approval for mesothelioma since 2004 and will potentially improve survival expectations in these patients,” commented Sanjay...

To view this content, please register now for access

It's completely free